A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stock has touched a 52-week low, dipping to $31.24, as investors respond to a ...
In surveys, parents of children with SMA and healthcare professionals in Sweden note the many ways the pandemic affected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback